Yirui Bio released its 2026 interim report. First-half revenue was 128 million yuan, up 17.5% year on year, but the company posted a loss of 19.73 million yuan, down 943.2% year on year. Net profit attributable to the parent after deducting non-recurring items widened from a loss of 2.06 million yuan in the same period last year to a loss of 23.54 million yuan. Net operating cash flow was negative 5.87 million yuan, down 28,750.3% year on year, and earnings per share were negative 0.0487 yuan. In the second quarter, revenue was 70.72 million yuan, up 18.0% year on year, while net profit attributable to the parent was a loss of 9.47 million yuan, down 266.5% year on year. As of the end of the second quarter, total assets were 1.48 billion yuan, down 2.9% from the end of the previous year, and net assets attributable to the parent were 874 million yuan, down 3.3%. The company's business is mainly concentrated in two areas: rapid food safety testing and animal diagnostics. Rapid food safety testing revenue reached 110 million yuan, up 4.86% year on year, while animal diagnostics revenue was 9.03 million yuan, a significant increase. The company said it is actively expanding in international markets, particularly in dairy testing, mycotoxins, and pesticide residues, to enhance the international influence of its brand.
Shenzhen Bioeasy Biotechnology Co. Ltd.First-half loss of 19.73 million yuan, down 943.2% year on year, with net profit after deducting non-recurring items widening to a loss of 23.54 million yuan.
